Medical management of dry eye disease

Developments in Ophthalmology

Volumn 41, Issue , 2008, Pages 54-74

  Tuft, S ^a   Lakhani, S ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS;

DRY EYE; HUMAN; LACRIMAL APPARATUS; LACRIMAL FLUID; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

DRY EYE SYNDROMES; HUMANS; LACRIMAL APPARATUS; OPHTHALMIC SOLUTIONS; TEARS;

EID: 47949091759     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000131073     Document Type: Article

References (55)

1. Lemp MA: Report of the National Eye Institute/Industry Work-shop on Clinical Trials in Dry Eye. CLAO J 1995;21:221-232.
2. Wilson SE, Liang Q, Kim WJ: Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. Invest Ophthalmol Vis Sci 1999;40:2185-2190.
3. Watanabe H: Significance of mucin on the ocular surface. Cornea 2002;21:S17-S22.
4. Sullivan DA, Wickham LA, Rocha EM, Kelleher RS, da Silveira LA, Toda I: Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland. Adv Exp Med Biol 1998;438:11-42.
5. Sullivan DA, Wickham LA, Rocha EM, Krenzer KL, Sullivan BD, Steagall R, Cermak JM, Dana MR, Ullman MD, Sato EH, Gao J, Rocha FJ, Ono M, Silveira LA, Lambert RW, Kelleher RS, Tolls DB, Toda I: Androgens and dry eye in Sjögren's syndrome. Ann NY Acad Sci 1999;876: 312-324.
6. Sullivan DA, Sullivan BD, Ullman MD, Rocha EM, Krenzer KL, Cermak JM, Toda I, Doane MG, Evans JE, Wickham LA: Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 2000;41:3732-3742.
7. Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, Richards SM, Suzuki T, Schaumberg DA, Sullivan RM, Dana MR: Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann NY Acad Sci 2002;966:211-222.
8. Rocha EM, Wickham LA, Huang Z, Toda I, Gao J, da Silveira LA, Sullivan DA: Presence and testosterone influence on the levels of anti- and pro-inflammatory cytokines in lacrimal tissues of a mouse model of Sjögren's syndrome. Adv Exp Med Biol 1998;438:485-491.
9. Pflugfelder SC: Anti-inflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-342.
10. Matoba AY, Harris DJ, Meisler DM, et al: Preferred Practice Pattern: Dry Eye Syndrome. San Francisco, American Academy of Ophthalmology, 2003.
11. Murube J, Benitez del Castillo JM, Chenzhuo L, et al: The Madrid triple classification of dry eye. Arch Soc Esp Oftalmol 2003;78:587-601.
12. Behrens A, Doyle JJ, Stern L, et al: Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006;25:900-907.
13. Huang FC, Tseng SH, Shih MH, Chen FK: Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes. Ophthalmology 2002;109:1934-1940.
14. Begley CG, Chalmers RL, Abetz L, Venkataraman K, Mertzanis P, Caffery BA, Snyder C, Edrington T, Nelson D, Simpson T: The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-4761.
15. Jones BR, Coop HV: The management of keratoconjunctivitis sicca. Trans Ophthalmol Soc UK 1965;85:379-390.
16. Gurny R, Ryser JE, Tabatabay C, Martenet M, Edman P, Camber O: Precorneal residence time in humans of sodium hyaluronate as measured by gamma scintigraphy. Graefes Arch Clin Exp Ophthalmol 1990;228:510-512.
17. Paugh JR, Chatelier RC, Huff JW: Ocular residence time of carboxymethylcellulose solutions. Adv Exp Med Biol 1998;438:761-767.
18. Wilson CG, Zhu YP, Frier M, Rao LS, Gilchrist P, Perkins AC: Ocular contact time of a carbomer gel (GelTears) in humans. Br J Ophthalmol 1998;82:1131-1134.
19. Christensen MT, Cohen S, Rinehart J, Akers F, Pemberton B, Bloomenstein M, Lesher M, Kaplan D, Meadows D, Meuse P, Hearn C, Stein JM: Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res 2004;28:55-62.
20. McDonald CC, Kaye SB, Figueiredo FC, Macintosh G, Lockett C: A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye 2002;16: 601-607.
21. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE: Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984;27: 459-461.
22. Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, Burr J, Stewart O, Quereshi S: Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004;88: 647-652.
23. Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M, Tsubota K: The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 2005;139:242-246.
24. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R, Kuwana M, Tsubota K, Ikeda Y, Oguchi Y: Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003;31:579-83.
25. Murube J, Murube E: Treatment of dry eye by blocking the lacrimal canaliculi. Surv Ophthalmol 1996;40:463-480.
26. Holden BA, Mertz GW: Critical oxygen levels to avoid corneal edema for daily and extended wear contact lenses. Invest Ophthalmol Vis Sci 1984;25:1161-1167.
27. Ehrlich DP: Therapeutic contact lenses. Optician 2001;222:28-32.
28. Lemp M, Caffery B, Lebow K, Lembach R, Park J, Foulks G, Hall B, Bowers R, McGarvey S, Young G: Omafilcon A (Proclear) soft contact lenses in a dry eye population. CLAO J1999;25: 40-47.
29. Lim L, Tan DTH, Chan WK: Therapeutic use of Bausch & Lomb Purevision contact lenses. CLAO J 2001;27:179-185.
30. Bacon AS, Astin C, Dart JKG: Silicone rubber contact lenses for the compromised cornea. Cornea 1994;13:422-428.
31. La Hood D, Sweeney DF, Holden BA: Overnight corneal oedema with hydrogel, rigid gas-permeable and silicone elastomer contact lenses. Int Contact Lens Clin 1988;15:149-154.
32. Kok J, Visser R: Treatment of ocular surface disorders and dry eyes with high gas-permeable scleral lenses. Cornea 1992;11:518-522.
33. Romero-Rangel T, Panagiota S, Cotter J, Rosenthal P, Baltatzis S, Foster S: Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000;130:25-32.
34. Smith GT, Mireskandari S, Pullum K: Corneal swelling with overnight wear of scleral contact lenses. Cornea 2004;23:29-34.
35. Willoughby CE, Batterbury M, Kaye SB: Collagen corneal shields. Surv Ophthalmol 2002;47: 174-182.
36. Holden BA, Sweeney DF, Sanderson G: The minimum precorneal oxygen tension to avoid corneal oedema. Invest Ophthalmol Vis Sci 1984;25:476-480.
37. Aquavella JV, Ruffini JJ, Lo Cascio JA: Use of collagen shields as a surgical adjunct. J Cat Refract Surg 1988;14:492-495.
38. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL 3rd, Tran-Johnson TK, Muscoplat CC, Trivedi M, Goldlust B, Gallagher SC: Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159:174-181.
39. Tsifetaki N, Kitsos G, Paschides CA, Alamanos Y, Eftaxias V, Voulgari PV, Psilas K, Drosos AA: Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12-week controlled study. Ann Rheum Dis 2003;62:1204-1207.
40. 2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res 1998;67:341-346.
41. - and fluid secretion. Am J Physiol 2001;281: C595-C602.
42. Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ: Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004;23: 784-792.
43. Ubels JL, Aupperlee MD, Jackson RS 2nd, Van Dyken SJ, McCartney MD: Topically applied 15-(S)-HETE stimulates mucin production by corneal epithelium. Adv Exp Med Biol 2002;506: 317-321.
44. Marsh P, Pflugfelder SC: Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999;106:811-816.
45. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE: The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003;136:593-602.
46. Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR, Childs R, Barrett AJ, Csakyet KG: Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 2004;33:1031-1035.
47. Sall K, Stevenson OD, Mundorf TK, Reis BL: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group [published erratum appears in Ophthalmology 2000;107:1220]. Ophthalmology 2000;107:631-639.
48. Kunert KS, Tisdale AS, Gipson IK: Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002;120: 330-337.
49. Stevenson D, Tauber J, Reis BL: Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-974.
50. Steinfeld SD, Demols P, Van Vooren JP, Cogan E, Appelboom T: Zidovudine in primary Sjögren's syndrome. Rheumatology (Oxford) 1999;38:814-817.
51. Schaumberg DA, Buring JE, Sullivan DA, Dana MR: Hormone replacement therapy and dry eye syndrome. JAMA 2001;286:2114-2119.
52. Pillemer SR, Brennan MT, Sankar V, Leakan RA, Smith JA, Grisius M, Ligier S, Radfar L, Kok MR, Kingman A, Fox PC: Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. Arthritis Rheum 2004;51:601-604.
53. Scott G, Yiu SC, Wasilewski D, Song J, Smith RE: Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. Am J Ophthalmol 2005;139: 1109-1110.
54. Matsuo T: Trehalose versus hyaluronan or cellulose in eyedrops for the treatment of dry eye. Jpn J Ophthalmol 2004;48:321-327.
55. Gronlund MA, Stenevi U, Lundeberg T: Acupuncture treatment in patients with keratoconjunctivitis sicca: a pilot study. Acta Ophthalmol Scand 2004;82:283-290.